COMMUNIQUÉS West-GlobeNewswire

BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections
04/11/2025
New FDA feedback confirms clinical pathway for fixed multi-phage cocktail BX011, expanding development into diabetic foot infections (DFI) and unlocking a major commercial opportunity NESS ZIONA, Israel, Nov. 04, 2025 ( [...]
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
04/11/2025
– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR [...]
RESET™ Clinical Trial Demonstrates Superior Pain Relief with SPRINT® PNS Compared to Standard Interventional Management for Chronic Low Back Pain
04/11/2025
The study met its Primary Endpoint of pain relief and showed that SPRINT PNS delivered significant improvements in patient-centric secondary endpoints CLEVELAND, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Published in the [...]
Renowned Pharma and Biotech Development Leader, Dr. Andreas Wallnöfer, is named to Optigo Biotherapeutics’ Board of Directors as the company advances to IND-enabling studies
04/11/2025
VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Optigo Biotherapeutics (“ Optigo ”) , an ophthalmology company pioneering next-gen treatments for retinal diseases, today announced that Dr. Andreas [...]
WORK Medical Technology Group LTD’s Subsidiary Retains a US$114,000 Service Contract from GemPharmatech Corporation
04/11/2025
Hangzhou, China, Nov. 04, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
Marius Pharmaceuticals Leads Effort to Redefine Women’s Health Through Testosterone Research
04/11/2025
All-female advisory board to guide Marius in addressing the unmet need for safe, effective testosterone therapies for women RALEIGH, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. , today announced [...]
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
04/11/2025
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. In vivo, CTX-10726 outperformed select [...]
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
04/11/2025
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and CEO, will present the phase 3 clinical trial of [...]
Anathapindika Health Increases Stock Ahead of Expected U.S. Surge
04/11/2025
The Buddhist-Inspired Natural Health and Wellness Brand Has Increased Its Production in the Midst of a U.S. Rollout Fort Lauderdale, FL, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The United States has the biggest health and [...]
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
04/11/2025
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors [...]
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
04/11/2025
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer [...]
PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China
04/11/2025
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia MENLO PARK, Calif., Nov. 04, 2025 (GLOBE [...]
Abalos Therapeutics to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025
04/11/2025
-- Combination with bispecific T-cell engagers amplifies T-cell recruitment and cytotoxic activity against tumor cells -- Düsseldorf, Germany, November 4, 2025 – Abalos Therapeutics announced today that it will present [...]
Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, into IND-Enabling Studies
04/11/2025
Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC 2025 DARKFOX [...]
Trading by management and close relations of management
04/11/2025
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
04/11/2025
CT-P72/ABP-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025 CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models, including Enhertu- [...]
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
04/11/2025
- CX-801 (PROBODY ® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of action and the ongoing [...]
LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
04/11/2025
Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD [...]
Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
04/11/2025
Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9th BOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology [...]

Pages